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ABSTRACT 
Objectives: To develop and validate a high-performance liquid chromatographic method for determination of diltiazem hydrochloride (DLZ) 
Methods: Mixture of n-hexane and 2-propanol (96:4, ratio) was added to plasma at sample preparation time followed by centrifuging the samples. 
The obtained upper organic layer was transferred and evaporated to dryness. The residue was reconstituted with a mobile phase and the 
supernatant was then injected onto the column. The mobile phase used was consisted of 0.2 M ammonium dihydrogen phosphate, acetonitrile, 
isopropyl alcohol and triethylamine (55:43:1.7:0.3, v/v) with pH adjusted to 4.5 using 85% phosphoric acid. The flow rate was 0.7 ml/min. UV 
detector set at 240 nm and samples were quantified using peak area. 
in 
human plasma.  
Results: A well-resolved DLZ peak and free of interference from endogenous compounds in plasma with a retention time of 6.03 min was achieved. 
Recovery of DLZ was satisfactory (≥ 91.3%) over the concentration range tested 0.25 - 20 µg/ml. LOD of this assay was 0.125 µg/ml and LOQ was 
0.25 µg/ml and, at this concentration, intra- and inter-day CV were 6.8 and 9.2 %, respectively. DLZ was found to be stable in plasma after storage at 
-80ºC, over 90 days. 
Conclusion: The HPLC method described in this article was simple, sensitive, selective, reproducible, linear, precise, accurate, stability indicating 
and requires only a small sample volume, lending it suitable for the determination of DLZ concentration in routine measurements for 
pharmacokinetic/bioavailability studies. 
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INTRODUCTION 
Diltiazem hydrochloride (DLZ) is a benzothiazepine calcium-channel 
antagonist with proven antianginal and antihypertensive efficacies 
[1, 2]. It is marketed for many years as a leading product for the 
treatment of cardiac disorders [3]. It can be given orally and 
intravenously for the treatment of angina pectoris, hypertension, 
arterial fibrillation and paroxysmal supra ventricular tachycardia 
[3]. DLZ like most calcium channel antagonists, it is a short acting 
compound and relies on a variety of slow release delivery systems to 
increase its duration of action and thereby decrease the dosing 
frequency [4]. The mechanism of action of DLZ is through decreasing 
the myocardial contractility and peripheral vascular resistance of 
smooth muscle.  
This is due to inhibiting calcium influx which resulted in reducing 
the coronary vasospasm. A vasodilation in arteriolesthereby can 
occur [5]. In this way, DLZ causes a modest lowering of heart rate 
and subsequently lowers systolic as well as diastolic blood pressures 
[6]. Recently, a large prospective study demonstrated that DLZ was 
as effective as β-blocker and thiazide diuretics in preventing 
cardiovascular events in hypertensive patients [7]. Thus, DLZ 
appears to be a first line alternative among antihypertensive drugs 
from evidence based point of view. Drug content, concentration, 
loading, kinetic release and pharmacokinetics issues in relation to DLZ 
can be addressed using in vitro, in vivo and other characteristic studies. 
The determination of analytes in biological and non-biological fluids 
using a reliable, sensitive and validated analytical method is required. A 
reversed phase high performance liquid chromatography (HPLC) with 
ultraviolet (UV) is most commonly applied among various analytical 
reported methods. Validation of the analytical method prior the drug 
analysis in various matrices and media must be conducted to determine 
the following parameters: specificity, sensitivity, linearity, limit of 
quantification (LOQ) and limit of detection (LOD), accuracy, precision 
(reproducibility of inter-day and intra-day variation), recovery 
(extraction efficacy) and drug stability in the sample (stability indicating 
method (SIM)).  
A number of analytical methods however have been developed for 
the determination of DLZ in biological samples, including using thin-
layer chromatography (TLC)[8], gas chromatography (GC)[9 - 11] 
and HPLC [12 – 20]. Although, they were generally using a reversed 
phase systems with UV detection but the procedure of sample 
preparation were differed, not sensitive and no comment on long-
term stability indicating method were made. Thus in this article, a 
sensitive, selective, reproducible and stability indicating HPLC-UV 
assay of DLZ concentration in human plasma was developed and 
validated for accuracy, precision, recovery, linearity and long-term 
stability. 
MATERIALS AND METHODS 
Materials 
DLZ was obtained from Sigma Aldrich (St. Louis, USA). HPLC grade 
acetonitrile and n-hexane were purchased from Merck (Darmstadt, 
Germany). 2−propanol and isopropyl alcohol were purchased from J. T. 
Baker (New Jersey, USA). Ammonium dihydrogen phosphate, 
phosphoric acid and triethylamine were obtained from BDH Chemicals 
Ltd (Poole. UK). All solvents and reagents used were of HPLC grade and 
used with further manipulations. 
Methods 
HPLC system for plasma samples 
A complete Shimadzu’s HPLC system (Shimadzu Corporation, Japan) 
was used consisting of a LC-10A vp Intelligent HPLC pump and a 
SPD-10A vp detector set at an operation wavelength of 240 nm and a 
Rheodyne 7725i injector fitted with a 50 µl sample loop (Rheodyne, 
USA). This HPLC system was typically used to analyze all the DLZ 
spiked samples. All obtained data were collected and processed by 
Shimadzu Class VP version 7.4 software. A Zorbax SB-C18 (Palo Alto, 
CA, USA) reversed phase column, (4.6 mm x 250 mm, 5 µm) fitted 
with refillable guard column (30 - 40 µm) packed with Perisorb RP-
18 (Upchurch Scientific, Oak Harbour, WA, USA) was used with a 
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mobile phase (degassed and filtered just before use) consisted of 0.2 
M ammonium dihydrogen phosphate, acetonitrile, isopropyl alcohol 
and triethylamine (55:43:1.7:0.3, v/v) with pH adjusted to pH 4.5 
using 85% phosphoric acid. The flow rate was 0.7 ml/min and 
samples were quantified using peak area. 
Sample preparation 
Prior to analysis, DLZ was extracted from the plasma samples 
according to the following procedure, 100 µl aliquot of plasma was 
measured accurately into an eppendorf micro-centrifuge tube and 
extracted by adding 400 µl extraction solvent of n-hexane and 2-
propanol (96:4 ratio) The mixture was vortex-mixed for 50 s (stuart 
scientific, UK). The sample was then centrifuged (Eppendrof, 
Hamburg, Germany) at 12 000 g for 5 min. The upper organic layer 
was transferred into a reactivial (Pierce Reacti-vial, USA) and 
evaporated to dryness at 40°C under a gentle stream of nitrogen gas. 
The residue was reconstituted with 100 µl of mobile phase and 60 µl 
aliquot of the supernatant was then injected onto the column. 
Assay validation 
A DLZ stock solution (1mg/ml) was prepared and stored at -80ºC 
until required. Six batches of DLZ standard curves were prepared in 
water and by spiking human serum or plasma with DLZ at final 
concentrations of 0.25, 0.5, 1, 2, 5, 10 and 20 µg/ml. The calibration 
standards were kept frozen (-80ºC) in the freezer until being used 
for the assay validation. Quantitataion was based on peak area of 
DLZ. The LOQ is defined as the concentration with signal-to-noise 
ratios of 10:1 whereas, LOD 3:1. Linearity was tested by minitab 15 
software using linear–square regression and lack-of-fit analysis.  
To determine intra-day accuracy and precision, six replicates of each 
concentration were determined in a single sample of each 
concentration were determined in a single day. For inter-day 
accuracy and precision evaluations, analyses were carried out on a 
single sample of each concentration daily for six consecutive days. 
The standard curves for DLZ were constructed by plotting area 
against concentration.  
DLZ concentrations were calculated using HPLC Shimadzu Class VP 
version 7.4 software. The absolute recovery (n=6) of the method 
was estimated by comprising peak areas of drug samples with drug 
solutions at corresponding concentrations. The stability of DLZ was 
tested in serum, at various concentrations. Short term stability (STS) 
was tested over 2days while long term stability (LTS) was tested 
over 90 days.  
RESULTS  
Chromatograms of plasma spiked with 10 µg/ml DLZ and plasma 
free of DLZ shows the DLZ peak with retention time of 
approximately 6.03 min was obtained and was well resolved and 
free of interference from endogenous compounds in plasma(Figure 
1A,Figure 1B). The total run time for each sample was 10 min. At 
least six batches of human plasma were tested. Thus, blank human 
plasma was used in the preparation of the calibration curves. DLZ 
was found to be stable in human plasma for at least a day at room 
temperature with no noticeable changes in DLZ-plasma 
concentrations. The calibration curve of DLZ in plasma (Figure 2) 
was linear over the concentration range 0.25 - 20 µg/ml (r2 0.9996 ± 
0.0008) with a mean intercept of 0.0696 ± 0.02(Table 1). Similarly, 
the calibration curve of DLZ in water(Figure 2) was linear over the 
concentration range 0.25 - 20 µg/ml (r2
 
 0.9999 ± 0.0004) with a 
mean intercept of -0.1104 ± 0.05 (Table 1). The absolute recovery, 
intra- and inter-day accuracy and precision values over the DLZ 
were over concentration range 0.25 -20 µg/ml (Table 2). Intra-day 
and inter-day accuracies were 91.5 - 108.4 % and 91.3 - 104.8 %, 
respectively, with precision (CV) ≤ 9.3 %. The LOD was 0.125 µg/ml 
whereas LOQ as the lowest concentration used in the construction of 
calibration curves was 0.25 µg/ml. At this concentration, intra- and 
inter-day C. V. were 6.8 and 9.2 %, respectively. This value is 
comparable to that reported by Parissi-Poulou et al.,[22], even 
though a smaller supernatant volume was injected in the study 
reported here. Furthermore, the present method was testing the DLZ 
stability in plasma before extraction. STS and LTS tests, of DLZ in 
human plasma after storage at -80ºC for 2, 30 and 90 days (Table 3). 
  
(A) Blank plasma (B) DLZ spiked plasma (10 µg/mL) 
Fig. 1: Chromatograms of DLZ obtained from (A) plasma free of DLZ and (B) plasma spiked with10 µg/ml DLZ. 
 
 
Fig. 2: Mean calibration curves for the determination of DLZ in water (x) and in human plasma (o) by HPLC using UV detector. (data are 
means ± S. D., n = 6). 
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Table 1: Comparison between r2
Standard Curve 





2 (mean ± SE) 
Intercept 
(mean ± SE) 
plasma spiked DLZ 0.9996 ± 0.0008 1.0029 ± 0.2 + 0.0696 ± 0.02 
water spiked DLZ 0.9999 ± 0.0004 1.0489 ± 0.3  - 0.1104 ± 0.05 
 














(C. V. %) 
0.25 109.4 4.4 91.8 6.8 104.8 9.2 
0.5 108.2 8.2 108.4 3.3 99.8 8.9 
1 98.1 8.4 94.9 8.2 102.4 9.0 
2 91.3 9.9 91.5 5.0 91.3 4.4 
5 101.4 6.6 102.8 3.1 103.1 9.3 
10 100.2 4.8 100.3 4.3 99.0 4.7 
20 102.5 0.4 101.5 0.4 100.3 1.7 
 
Table 3: DLZ stability in human plasma after 2, 30 and 90 days at -80ºC (data are means ± S. D., n=6). 
[DLZ] (µg/mL) [DLZ ] at 2 days (µg/mL) [DLZ ] at 30 days (µg/mL) [DLZ ] at 90 days (µg/mL) 
0.50 0.49 ± 0.10 0.49 ± 0.30 0.48 ± 0.50 
1.0 0.9 ± 0.40 0.9 ± 0.50 0.9 ± 0.70 
10.0 9.9 ± 0.50 9.8 ± 0.96 9.8 ± 1.30 
 
DISCUSSION 
This paper presents analytical methods for the determination of DLZ 
in human plasma. Samples from any further in vivo and 
pharmacokinetic studies can be analysed for DLZ using this current 
HPLC method. A number of analytical methods have been reported 
for determination of DLZ in plasma [8 - 21]. However, the HPLC 
method developed here was based on the method reported by 
Parissi - Poulou et al.,[22], but with some modifications to the 
mobile phase, extraction solvent, pH and HPLC flow rate.  
The mobile phase was modified to contain 55% of 0.2 M potassium 
dihydrogen phosphate, 43% of acetonitrile,1.7% of isopropyl alcohol 
and 0.3% triethylamineas compared to that of Parissi - Poulou et 
al.,[22] which consists only 0.5 M potassium dihydrogen phosphate 
and acetonitrile at a ratio of 30:70. The addition of 1.7% isopropyl 
alcohol and increase the buffer pH value from 2.5 to 4.5 played an 
important role in producing sharp and well-resolved drug peaks free 
from interference from endogenous compounds in the plasma.  
The acetonitrile content in the mobile phase was also found to be 
critical in separating DLZ from endogenous compounds and the best 
resolution was achieved at an acetonitrile concentration of 43% (v/v). 
When the acetonitrile content was below 35% (v/v), the elution time of 
DLZ was increased and the peak was not well separated from an 
endogenous peak being eluted later. Two peaks gradually overlapped as 
the acetonitrile content was further reduced to 30% (v/v).  
Since DLZ is a weakly basic amine, the interaction between its amino 
group and the stationary phase could lead to peak tailing and 
broadening[23]. The use of short-chain tertiary amine modifiers 
such as triethylamine is very effective in improving peak symmetry 
and reducing retention of solutes with amino functional groups[24]. 
Therefore, triethylamine in 0.3% was added into the mobile phase to 
improve the resolution as well as peak symmetry of DLZ. 
It is evident that a linear correlation is existed between the peak 
area ratio of plasma spiked DLZ and water spiked DLZ. This result 
also demonstrates that no considerable interference is existed. The 
extraction recovery of DLZ was determined by comparing the peak 
area obtained by direct injection of standard aqueous solutions to 
those obtained after the plasma extraction procedure. An extracting 
solvent mixture of n-hexane and 2-propanol (96:4 v/v) was found to 
give satisfactory recoveries for DLZ and provide cleaner 
chromatograms as compared to using n-hexane, diethyl ether, 
methyl tertiary butyl ether, ethyl acetate or chloroform alone as the 
extracting solvent.  
DLZ was found to be stable in plasma after storage at -80ºC for 2, 30 
and 90 days. No considerable differences were observed. The result 
demonstrates that the assay is selective, stable and sufficiently 
sensitive for the determination of DLZ concentrations in any future 
pharmacokinetic/bioavailability studies. 
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CONCLUSION 
In conclusion, the HPLC method described here is simple, sensitive, 
selective, reproducible, linear in the specified range, precise, 
accurate, stability indicating and requires only a small sample 
volume, lending it suitable for the determination of DLZ 
concentration in routine measurements for pharmacokinetics / 
bioavailability studies. 
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